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Cholangiocarcinoma is a rare and aggressive malignancy of the biliary tract. Complete 
surgical resection can be curative, but the majority of patients are diagnosed with advanced 
disease and usually die within a year of diagnosis. Most deaths are attributable to local 
disease progression rather than distant metastases, supporting the use of locoregional 
therapies. There is evidence that locoregional therapies can provide local tumor control 
resulting in increased survival while avoiding some of the side effects of systemic treatments, 
increasing potential treatment options for patients who may be unsuitable for systemic 
palliative treatments. This review considers the evidence for locoregional therapies in 
cholangiocarcinoma, which can be classified into endoscopic, vascular, percutaneous and 
radiation oncological therapies. Current guidelines do not recommend the routine use of 
locoregional therapies due to a lack of prospective data, but the results of ongoing trials are 
likely to increase the evidence base and impact on clinical practice.
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Practice points
 ●  Palliative endoscopic biliary stenting for malignant biliary obstruction improves survival, but routine biliary drainage prior to curative-
intent surgery increases the rate of complications.
 ●  Radiofrequency ablation is a thermal ablative technique that can improve biliary drainage in malignant biliary obstruction, either as a 
primary treatment or to treat tumor ingrowth in uncovered metal stents. However, prospective data supporting its efficacy are lacking.
 ●  Microwave ablation and irreversible electroporation are alternative ablative techniques that may allow for treatment of unresectable 
intrahepatic cholangiocarcinomas that lie near to essential biliary or vascular structures, although prospective data are needed to assess 
their efficacy.
 ●  Photodynamic therapy can maintain biliary patency in the palliation of cholangiocarcinoma and may improve progression-free survival, 
although there is a paucity of high-quality data to support its use.
 ●  There is evidence that hepatic artery-based therapies (selective internal radiotherapy, hepatic artery infusion and transarterial 
chemoembolization) can provide local tumor control. Although current guidelines do not recommend their routine use, they acknowledge 
that radiotherapy and selective internal radiotherapy may be considered after first line chemotherapy.
 ●  Evidence for the use of external beam radiotherapy with conventional fractionation, with or without concomitant chemotherapy, is 
conflicting and largely limited to retrospective analyses. Brachytherapy has been used in multimodal neoadjuvant chemoradiotherapy 
regimens prior to liver transplantation for unresectable perihilar cholangiocarcinoma, with encouraging long term survival rates. There is 
no established role for palliative brachytherapy.
 ●  Stereotactic body radiotherapy and proton beam therapy allow for higher doses of radiation to be given while limiting radiation damage 
to surrounding normal tissue; early phase trials have shown promising results.
 ●  Patients should be encouraged to participate in clinical trials investigating the efficacy of locoregional therapies in cholangiocarcinoma to 
provide evidence for their use.
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Cholangiocarcinomas are bile duct tumors aris-
ing from biliary tree epithelia [1]. They are clas-
sified as intrahepatic, perihilar or distal extra-
hepatic based on their position along the biliary 
tract. Worldwide, the incidence of intrahepatic 
cholangiocarcinoma is increasing whereas perihi-
lar and distal extrahepatic cholangiocarcinomas 
are decreasing [2]. It is usually diagnosed at an 
advanced stage due to late development of symp-
toms and aggressive tumor biology [3]. Patients 
with unresectable disease often die within a 
year of diagnosis, most commonly from biliary 
obstruction leading to liver failure or biliary sep-
sis [4]. Notably, these causes of death are attrib-
utable to local disease progression rather than 
distant metastases and several therapies attempt 
to improve survival by controlling locoregional 
progression. This review considers the evidence 
supporting locoregional therapies for cholangio-
carcinoma, which can be classified into endo-
scopic, vascular, percutaneous and radiation 




Preoperative stenting involves the insertion of one 
of more stents into the bile duct to improve bil-
iary drainage prior to surgery. Although animal 
experiments suggested that preoperative biliary 
stenting reduced mortality by improving endo-
toxaemia and nutritional status [5], a randomized 
controlled trial (RCT) comparing surgery with 
or without preoperative endoscopic biliary stent-
ing (EBS) in malignant distal biliary obstruc-
tion found no mortality reduction, higher rates 
of serious complications (74 vs 39%) and more 
frequent hospital readmissions with preoperative 
EBS [6]. A subsequent cochrane review did not 
recommend their routine use [7]. Although there 
are no RCTs assessing preoperative EBS in hilar 
strictures, a systematic review and meta-analysis 
(SRMA; 11 nonrandomized studies, n = 711) 
found no survival benefit from preoperative 
EBS with an increased risk of postoperative 
complications [8]. However, preoperative EBS 
is necessary in certain circumstances, including 
acute cholangitis (most commonly secondary to 
contrast injection during Endoscopic Retrograde 
Cholangiopancreatography (ERCP)), severe 
jaundice and before starting neoadjuvant treat-
ment [5,9,10]. In these circumstances, covered 
self-expanding metal stents (SEMS) are supe-
rior to plastic stents. An SRMA (five studies, 
n = 704) found reduced re-intervention rates 
(3.4 vs 14.8%) and pancreatic fistulae (5.1 vs 
11.8%) with SEMS for distal biliary obstruction, 
although none of the cohort had cholangiocarci-
noma [11]. A small retrospective analysis (n = 27) 
found a reduced failure rate from SEMS for pre-
operative stenting of the future liver remnant 
in perihilar cholangiocarcinoma (0/10 SEMS 
vs 7/17 plastic stents), although the authors 
acknowledged limitations of the study design 
for assessing superiority [12].
Palliative stenting
The technique for palliative stenting is the same as 
preoperative stenting and is used to improve bil-
iary drainage and prevent death from liver failure 
or biliary sepsis. In patients with a life expectancy 
of more than 4 months, SEMS are superior to 
plastic stents [13]. Two recent SRMAs comparing 
SEMS and plastic stents (11 retrospective and pro-
spective studies, n = 947 and 20 RCTs, n = 1713, 
respectively) found SEMS to be associated with 
longer stent patency, lower re-intervention rates 
and lower rates of cholangitis [14,15].
Tumor ingrowth in uncovered SEMS can 
lead to recurrent biliary obstruction. An SRMA 
(14 RCTs, n = 1417) comparing covered versus 
uncovered SEMS found no significant differ-
ence in time to stent blockage/dysfunction or 
overall survival (OS), although the cause of stent 
blockage (tumor ingrowth in uncovered SEMS 
vs tumor overgrowth in covered SEMS) was 
significantly different [16]. Covered SEMS were 
also more likely to migrate. However, subgroup 
analysis in another SRMA found uncovered 
SEMS to be associated with a higher OS [15].
There is conflicting evidence for the use of 
bilateral stents in unresectable hilar cholan-
giocarcinoma. A review in 2013 identified two 
RCTs and four retrospective studies comparing 
unilateral versus bilateral stents [17]. Although 
three studies advocated unilateral stenting and 
three advocated bilateral stenting, both RCTs 
recommended unilateral stenting. As draining 
25–30% of liver volume is considered adequate 
for the resolution of obstructive jaundice in 
most patients, bilateral stenting is unlikely to 
provide a significant benefit in most patients [17]. 
However, bilateral stenting is required if jaun-
dice does not improve with unilateral drainage 
or there is sepsis within the contralateral lobe.
Endoscopic ultrasound-guided biliary 
drainage is an alternative endoscopic tech-
nique for patients who have failed or have 
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contraindications to EBS and percutaneous 
drainage. A stent can be placed transduodenally 
or by forming a hepaticogastrostomy [18]. An 
SRMA (42 studies, n = 1192) found this tech-
nique to have a 94.7% technical success rate and 
91.7% functional success rate but a complication 
rate of 23.3% [19]. Complications include bleed-
ing (4%), bile leak (4%), pneumoperitoneum 
(3%) and stent migration (<3%).
●● Radiofrequency ablation
Radiofrequency ablation (RFA) involves the pas-
sage of an electrical probe into the biliary tree 
to the site of the tumor, creating a therapeutic 
heating zone causing coagulative necrosis [20]. 
Endoscopic RFA can be used palliatively either 
as a primary treatment to resolve obstructive 
jaundice or to treat tumor ingrowth in uncovered 
SEMS, although there are no published RCTs on 
its use. A recent SMRA (nine studies, n = 263, 
173 with cholangiocarcinoma) reported a tech-
nical success rate of 96.8%, a mean bile duct 
diameter increase of 3.5 mm and a median stent 
patency duration of 7.6 months [21]. The pooled 
adverse event rate was 17%, the most common 
complications being pain (11%), cholangitis 
(8%) and cholecystitis (4%). Three patients 
had late-onset biliary bleeding, two of whom 
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died [22]. Pooled 30-day, 90-day and 2-year mor-
tality was 1.5, 20.9 and 48.1%, respectively. A 
retrospective matched cohort study (n = 66, 36 
with cholangiocarcinoma) comparing stenting 
with or without RFA found age, chemotherapy 
and RFA to be predictors of survival on mul-
tivariable Cox proportional hazard analysis 
(p = 0.012) [23]. RCTs are required to provide 
higher quality evidence of the efficacy of RFA 
in cholangiocarcinoma.
●● Photodynamic therapy
Photodynamic therapy (PDT) is an ablative 
technique involving intravenous administration 
of a photosensitizing agent followed by intralu-
minal laser irradiation [24]. An SRMA (10 stud-
ies, n = 402) comparing PDT (percutaneous or 
endoscopic) versus stenting alone in unresect-
able cholangiocarcinoma found a significant 
increase in OS with PDT (413 vs 183 days) 
with no significant difference in rates of chol-
angitis, although 10.5% of PDT patients had 
photosensitivity reactions [25]. This SRMA did 
not include an RCT comparing EBS versus EBS 
with PDT that was stopped due to worse OS in 
the PDT group (5.6 vs 8.5 months) [26]. A recent 
RCT (n = 20) comparing chemotherapy with 
EBS versus chemotherapy with EBS and PDT 
found longer median progression-free survival 
(PFS) in the group having PDT [27].
●● Brachytherapy
Intraluminal brachytherapy involves the inser-
tion of Iridium-192 wires percutaneously or 
endoscopically. It has been used as part of neoad-
juvant chemoradiotherapy regimes prior to ortho-
topic liver transplantation (OLT) for unresect-
able perihilar cholangiocarcinoma, but is more 
commonly used in the palliative setting [28,29]. 
A recent retrospective analysis using the US sur-
veillance, epidemiology and end results (SEER) 
database compared external beam radiotherapy 
(EBRT; n = 1188) versus EBRT with brachy-
therapy (n = 91) [30]. After excluding patients 
with metastatic disease, there was only a trend 
toward improved survival with the addition 
of brachytherapy to EBRT (10 vs 13 months, 
p = 0.08). The most recent prospective study 
(2007, n = 42) comparing percutaneous SEMS 
versus percutaneous SEMS with intraluminal 
brachytherapy found survival to be higher with 
the addition of brachytherapy (298 vs 388 days, 
p < 0.05) [31]. Based on these promising results, 
further  prospective trials are warranted.
vascular therapies
A number of therapies are delivered to the tumor 
via the hepatic artery to provide local tumor 
control: hepatic artery embolization, selective 
internal radiotherapy, hepatic artery infusion 
and transarterial chemoembolization (TACE).
●● Hepatic artery embolization
Hepatic artery embolization (HAE), also known 
as transarterial embolization, causes tissue 
hypoxia by infusing the hepatic arterial supply 
of the tumor with an embolic agent. Although 
HAE is infrequently used compared with TACE, 
there is little evidence to support the superior-
ity of TACE over HAE in cholangiocarcinoma. 
In a multi-institutional retrospective analysis 
(n = 198), only 13 patients (6.6%) underwent 
HAE compared with TACE (70.2%) or selective 
internal radiotherapy (SIRT) (23.2%) [32]. There 
was no significant difference in survival based 
on the treatment type (median OS of 13.4, 14.3 
and 11.3 months for TACE, HAE and SIRT 
respectively), although no subgroup analysis on 
complication rates or tumor responses between 
the different treatments was reported.
●● Selective internal radiotherapy
SIRT, also known as transarterial radio-embo-
lization, is arterially delivered brachytherapy 
involving infusion of 90yttrium resin or glass 
microspheres into the tumor’s blood supply 
resulting in mechanical embolization of the 
tumor vasculature and local delivery of radia-
tion. A recent review identified eight studies 
(2008–2016) with data on outcomes following 
SIRT for intrahepatic cholangiocarcinoma [33]. 
Median survival ranged from 4.4 to 52 months, 
although many patients had also undergone 
prior chemotherapy making interpretation of 
survival data difficult [34–39]. A recent system-
atic review and pooled analysis (12 studies, 
n = 298) found SIRT to provide partial tumor 
responses in 28% and stable disease in 54% 
of patients 3 months post-treatment, although 
heterogeneity in study designs precluded a 
meta-analysis [40]. Factors predictive of a better 
response include Eastern Cooperative Oncology 
Group performance status 0, no portal vein 
thrombosis, peripheral rather than infiltrative 
tumors and a tumor burden <25% of total liver 
volume [34–36]. Although postradioemboliza-
tion syndrome is usually mild and self-limiting, 
reported grade III/IV side effects include hepatic 
enzyme dysfunction and rarely gut ischemia or 
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peptic ulceration secondary to inadvertent deliv-
ery of microspheres into vessels supplying the 
 gastrointestinal tract [33].
●● Hepatic artery infusion
Hepatic artery infusion (HAI), also known 
as transarterial chemoinfusion, involves the 
radiological or surgical placement of an arterial 
catheter attached to an infusion pump allow-
ing for the delivery of chemotherapeutic agents 
directly to the tumor [41]. A recent review iden-
tified 11 studies (2002–2015) investigating the 
use of HAI (n = 299, 232 with cholangiocarci-
noma) [42]. Complete or partial responses were 
seen in 7.5–66.6%, stable disease in 18.2–64% 
and conversion to resectability in 3.8–27.3%. 
Median OS ranged from 4.2 to 31.1 months 
with reported minor and major complications 
of 0–100% and 0–13%, respectively [43–53]. A 
Phase II trial investigating the use of HAI in 
37 patients with perihilar cholangiocarcinoma 
found complete and partial tumor responses in 
six patients (16.2%) and 19 patients (51.4%), 
respectively [54]. Median PFS was 12.2 months 
and median OS was 20.5 months. Patients were 
more likely to respond to treatment if they had 
periductal-infiltrating rather than mass-forming 
tumors (complete or partial response in 82.6 vs 
42.9%, 1 year OS 82.4 vs 21.4%).
●● TACe
Conventional TACE (cTACE) involves injec-
tion of chemotherapeutic agents followed by 
embolization of the tumor microcirculation 
with foam or microspheres. Drug-eluting bead 
TACE (DEB-TACE) uses embolizing beads 
loaded with chemotherapeutic agents, and 
degradable starch microsphere TACE (DSM-
TACE) is similar to DEB-TACE but with rapid 
degradation (25–40 min) of the microspheres 
after administration [55]. A recent systematic 
review (nine studies, n = 421) reported on the 
utility of cTACE in the treatment of inoperable 
intrahepatic cholangiocarcinoma [56]. Median 
OS from diagnosis and from procedure ranged 
from 12 to 25.2 months and 9.1 to 16.3 months, 
respectively. Three studies showed a significant 
survival benefit compared with patients receiv-
ing best supportive care alone [56]. Major compli-
cations included myocardial infarction, pulmo-
nary edema/infarction, hematological and liver 
toxicities, hepatic artery dissection, anaphylaxis 
and one reported death. The same review also 
identified five studies (n = 83) reporting on 
the use of DEB-TACE in cholangiocarcinoma. 
Median OS from procedure ranged from 11.7 
to 17.5 months respectively, similar to the OS 
reported for cTACE.
A meta-analysis in 2013 (16 studies, n = 542) 
reported on the imaging responses, complica-
tions and OS following hepatic artery-based 
therapies (cTACE, DEB-TACE, DSM-TACE 
and HAI) for unresectable intrahepatic cholan-
giocarcinoma [57]. Weighted median OS from 
diagnosis and from procedure was 15.7 and 
13.4 months, respectively. Tumor responses 
(based on RECIST criteria) were complete in 
1.6%, partial in 21.2%, stable in 53.9% and pro-
gressive in 23.2%. Grade III/IV complications 
occurred in 18.9% of patients, with a 30-day 
mortality of 0.7%. However, the meta-analysis 
did not directly compare the different therapies 
and there was no comment on  conversion to 
resectability.
There are no RCTs directly comparing the 
vascular therapies TACE, SIRT and HAI. An 
SRMA in 2015 (20 studies, n = 657) found 
median OS to be greatest for HAI (22.8 months) 
followed by SIRT (13.9 months) and cTACE/
DEB-TACE (12.4 and 12.3 months, respec-
tively) [58]. Response to therapy (complete or 
partial) was also highest with HAI (HAI 56.9%, 
SIRT 27.4% and TACE 17.3%). However, the 
rate of grade III/IV complications was also high-
est following HAI (0.35, 0.32 and 0.26 events 
per patient for HAI, DEB-TACE and cTACE, 
respectively). This may be due to an altered risk 
profile leading to selection bias (HAI requires 
surgical or radiological implantation of a pump 
or port, whereas the other modalities do not).
Percutaneous therapies
●● Biliary stenting, radiofrequency ablation, 
photodynamic therapy & brachytherapy
Stenting, RFA, PDT and brachytherapy can all 
be performed percutaneously as well as endo-
scopically. Two retrospective studies (n = 169) 
reported fewer infectious complications from 
preoperative percutaneous biliary drainage for 
perihilar cholangiocarcinoma (65 vs 10.4% 
and 48 vs 9%) [59,60] which has led to the 
DRAINAGE RCT comparing percutaneous 
stenting with EBS (currently recruiting) [61]. 
There is no evidence for the superiority of percu-
taneous versus endoscopic RFA in cholangiocar-
cinoma, although no RCTs have been performed 
to date [62]. A recent retrospective study (n = 37) 
found that although there was no difference 
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in OS, patients having percutaneous PDT for 
unresectable perihilar cholangiocarcinoma had 
longer hospital admissions than those having 
endoscopic PDT (37 vs 63 days) [63]. There are 
no published studies comparing percutaneous 
versus endoscopic intraluminal brachytherapy.
●● Microwave ablation
Microwave ablation (MWA) is a thermal abla-
tive technique that generates heat by creating 
an electromagnetic field [64]. Few articles have 
been published on its use in cholangiocarci-
noma. Yu et al. published the first series of 15 
patients with 24 histologically proven inoperable 
intrahepatic cholangiocarcinomas treated with 
ultrasound-guided percutaneous MWA [65]. 
They reported a technical success rate of 91.7% 
and a median OS after treatment of 10 months, 
although an undetermined number of patients 
went on to have other local or systemic treat-
ments. Complications included two liver 
abscesses, one patient with needle-track tumor 
seeding and one patient with subcapsular bleed-
ing. A similar trial used either RFA or MWA 
to treat 18 patients with histologically proven 
intrahepatic cholangiocarcinoma (eight primary 
and ten postoperative recurrences) [66]. In the 
six patients undergoing MWA (all with solitary 
nodules), median OS was 13.5 months with 
three patients surviving more than 5 years.
Yang et al. published a retrospective study 
investigating the safety and efficacy of percutane-
ous MWA with simultaneous TACE in patients 
with advanced or recurrent intrahepatic cholan-
giocarcinoma (n = 26, 39 tumors) [67]. Thirty-
six tumors were completely ablated on follow-up 
imaging (92.3%). Median PFS and OS from 
treatment was 6.2 and 19.5 months respectively 
with a 2-year OS of 61.5%. No major com-
plications occurred, with fever (88.5%), pain 
(84.6%) and thrombocytopenia (11.5%) being 
the most common minor complications. These 
encouraging results warrant RCTs comparing 
MWA versus MWA with TACE, as well as stud-
ies comparing MWA with other thermal ablative 
techniques such as RFA.
●● irreversible electroporation
Irreversible electroporation is a nonthermal 
ablative technique that uses pulsed electri-
cal current to induce cellular apoptosis with-
out disrupting the surrounding extracellular 
matrix, preventing damage to nearby vascular 
and biliary structures [68]. Data pertaining to 
its use in cholangiocarcinoma are limited. An 
SRMA this year (nine studies, n = 300, 21 cases 
being cholangiocarcinoma) found a significant 
reduction in tumor diameter (standardized 
mean difference 0.447, 95% CI: 0.189–0.704) 
with transient rises in liver enzymes associated 
with the procedure [69]. There were seven major 
complications reported; four hepatic abscesses, 
one bile duct dilatation, one cardiac arrhythmia 
and one portal vein thrombosis. Survival data 
were not reported and the current data should be 
 considered preliminary and experimental.
Radiation oncological therapies
●● external beam radiotherapy
The role of conventionally fractionated adjuvant 
radiotherapy remains unestablished. A recent 
retrospective analysis from the US National 
Cancer Database examined the effect on sur-
vival of postoperative radiotherapy for intra-
hepatic cholangiocarcinoma (n = 2897, 525 
having had radiotherapy) [70]. Although there 
was a trend toward improved survival following 
radiotherapy in patients with negative lymph 
nodes but positive (R1/R2) resection margins, 
this disappeared after adjusting for other clin-
icopathological factors (p = 0.923). The authors 
concluded that radiotherapy should not be rou-
tinely administered postoperatively. A system-
atic review in 2015 identified three retrospective 
analyses, one SRMA, two SEER studies and one 
prospective study investigating the role of adju-
vant radiotherapy in cholangiocarcinoma [71]. 
Two of the retrospective analyses found higher 
5-year OS following EBRT in perihilar chol-
angiocarcinoma versus resection alone (33.9 
vs 13.5% and 19 vs 11%) and the SRMA 
(seven studies) found adjuvant radiotherapy 
to improve survival in extrahepatic cholangio-
carcinoma (pooled hazard ratio 0.62, 95% CI: 
0.48–0.78, p < 0.001) [72–74]. The third analysis, 
although finding no increase in OS, found an 
improvement in disease-free survival favoring 
postoperative radiotherapy in patients with 
positive resection margins (5-year disease-free 
survival 13.9 vs 4.1%, p = 0.042) [75]. However, 
this could be due to the small number (<10) 
of 5-year survivors and may not represent a 
true difference. In the two SEER analyses, one 
found adjuvant radiotherapy to increase OS in 
intrahepatic cholangiocarcinoma (median OS 
6 vs 11 months, p = 0.014, n = 1234) whereas 
the other found no effect in extrahepatic chol-
angiocarcinoma (18 vs 18 months, p = 0.8, 
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n = 1491) [76,77]. This may be due to patient 
selection bias, challenges in delivering higher 
radiation doses to extrahepatic tumors, or 
the unclear inclusion or exclusion of perihilar 
tumors in the latter study. A prospective study 
of EBRT to 50 patients with locally advanced 
perihilar cholangiocarcinoma found no sur-
vival benefit from the addition of radiotherapy 
(median OS 20 vs 20 in resected patients and 8 
vs 12.5 months in palliated patients) [78].
Palliative radiotherapy is not widely used 
in cholangiocarcinoma. One SEER analysis 
(n = 2685) found palliative radiotherapy to be 
superior to no treatment in extrahepatic chol-
angiocarcinoma (9 vs 4 months) [79]. However, 
data on chemotherapy were not available making 
interpretation of the results difficult.
●● Stereotactic body radiotherapy
Stereotactic body radiotherapy (SBRT) involves 
highly localized external beam radiother-
apy with a high dose per fraction; typically 
3–5 fractions of radiotherapy delivered over 
2 weeks [80]. Because a much smaller margin 
of normal tissue is irradiated due to its spe-
cific targeting, higher doses of radiation can be 
delivered while limiting damage to surrounding 
normal tissue. Evidence for its use in cholangio-
carcinoma is restricted to retrospective single 
institution studies. Jung et al. reported out-
comes in patients with unresectable primary or 
recurrent postoperative intrahepatic cholangio-
carcinoma treated with SBRT (n = 53) or con-
ventional EBRT plus SBRT boost (n = 5) and 
found a median OS of 10 months [81]. Grade 
I/II complications occurred in 29% and grade 
III/IV complications in 10% with one mortal-
ity from gastric perforation. Mahadevan et al. 
used SBRT in 32 patients with unresectable 
or recurrent intrahepatic or perihilar cholan-
giocarcinoma and found SBRT to be associ-
ated with a median OS of 17 months [82]. 
Sandler et al. recently reported on the use of 
SBRT as a neoadjuvant therapy prior to OLT 
for unresectable intrahepatic or perihilar chol-
angiocarcinoma (n = 31) [83]. Of the 18 patients 
in the neoadjuvant subgroup, 14 were listed for 
OLT, of whom four patients underwent OLT 
and a fifth patient underwent surgical resec-
tion. Median OS was significantly higher in the 
five patients who underwent OLT or surgery 
(31.3 vs 12.7 months), with duodenal stric-
ture/obstruction or hemorrhage being the most 
 common major complications.
●● Proton beam therapy
Instead of photon waves in EBRT, proton beam 
therapy (PBT) uses charged particles to deliver 
radiotherapy for greater dose conformation to 
the target volume. Like SBRT, this results in 
significantly reduced doses to surrounding tis-
sues [84]. A retrospective analysis in 28 patients 
with new or recurrent inoperable cholangio-
carcinoma undergoing PBT reported 1-year 
PFS and OS of 29.5 and 49%, respectively [85]. 
However, toxicities were common; 29 grade I, 
16 grade II and eight grade III toxicities were 
reported. Grade III toxicities included duode-
nal ulceration/hemorrhage/stenosis, cholangitis 
and biliary stenosis. A prospective multicenter 
Phase II study of PBT (n = 83, 44 having 
cholangiocarcinoma) found a median PFS of 
8.4 months and median OS of 22.5 months 
in the cholangiocarcinoma subgroup [86]. A 
similar study using curative-intent (n = 12) or 
palliative PBT (n = 8) for unresectable intrahe-
patic cholangiocarcinoma found curative-intent 
PBT achieved a median OS of 27.5 months 
with 1-year local disease control achieved in 
88% [87].
Future perspective
Several prospective clinical trials are currently 
underway to try to establish the role of vari-
ous locoregional therapies in cholangiocarci-
noma, and the results of these may influence 
future use. Examples include the SIRCCA trial 
(chemotherapy ± SIRT), the DELTIC trial 
(chemotherapy ± DEB-TACE) and ABC-07 
(chemotherapy ± SBRT). Due to the rarity of 
cholangiocarcinoma, a move away from RCTs 
and toward novel trial designs such as adaptive 
clinical trials or umbrella studies may allow 
for the simultaneous assessment of multiple 
therapies or treatment schedules, allowing 
for earlier identification of effective therapies. 
Novel trial design is especially important as 
the future management of advanced cholan-
giocarcinoma is likely to be multimodal and 
involve combined therapies, such as the combi-
nation of MWA and TACE by Yang et al. [67]. 
Exciting developments in nanomedicine may 
also augment existing therapies. For example, 
Spring et al. recently developed a nanolipo-
some containing a photosensitizer and a mul-
tikinase inhibitor that could be activated by 
near infrared light to provide simultaneous 
PDT and local release of biological agents [88]. 
Such treatments that exert their effects through 
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different mechanisms may provide patients 
with improved locoregional control and sub-
sequent improved survival.
Guidelines & conclusion
Due to a lack of prospective data and RCTs on 
the majority of locoregional therapies, recom-
mendations for their use in guidelines are lim-
ited. The British Society of Gastroenterology 
cholangiocarcinoma guidelines (2012) did not 
recommend the use of PDT based on avail-
able data [9]. The International Liver Cancer 
Association guidelines (2014) did not recom-
mend EBRT or HAI in the treatment of unre-
sectable intrahepatic cholangiocarcinoma based 
on current evidence [89]. TACE, SIRT and RFA 
were acknowledged to provide some local tumor 
control, but could not be recommended as stand-
ard therapy until further clinical trials demon-
strated their efficacy. The European Society of 
Medical Oncology guidelines (2016) state that 
radiotherapy and SIRT may be considered after 
first line chemotherapy [90]. Patients should be 
encouraged to participate in clinical trials inves-
tigating locoregional therapies to provide better 
evidence for their use. Trials should also not only 
focus on survival as a primary outcome but also 
on quality of life as a vital part of assessing the 
efficacy of any treatment. The results of several 
ongoing trials will provide evidence for the use 
of locoregional therapies in the palliation of 
cholangiocarcinoma.
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